Fintech valuations are soaring at the late stage, and one Silicon Valley VC is warning of a bubble

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. HENNY RAY ABRAMS/AFP/Getty ImagesFintech valuations in the US and Europe are soaring as investors pile into digital finance opportunities.  Late-stage fintech startups saw a record year of funding in 2020. Some sub-sectors of fintech may get left behind and it's a bubble waiting to pop, according to Thomvest Ventures managing director Don Butler. Visit Business Insider's homepage for more stories. Fintech valuations are booming.  This flourishing sector for startups is a broad church, comprising payments, financial markets, challenger banking, insurance, and lending. Its emergence is down to factors such as consumer willingness to shop and bank online, and distrust and dissatisfaction with traditional financial providers. The number of fintech mega-deals rose in the US to a decade high last year, with 44 transactions logging $12.2 billion, according to PitchBook data. The median pre-money valuation for VC-backed, late-stage fintech companies in North America and Europe from 2019 was a record $73.8 million. That figure for last year, as of Q3 2020, was $95 million. Despite the coronavirus pandemic, fintech valuations were breaking records.  Notable examples include stock trading app Robinhood which raised funding at an $11.2 billion valuation last year; buy now, pay later startup Klarna which raised at $10.65 billion; To keep reading about Fintech valuations are soaring at the late stage, and one Silicon Valley VC is warning of a bubble, Click on the link. Seoul, Korea
http://dlvr.it/RrHgvH

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint